Cargando…
Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty
BACKGROUND: Gonadotropin releasing hormone agonists (GnRHa) are well established as a standard of care for the treatment of central precocious puberty (CPP) worldwide. While numerous delivery systems and routes of administration exist, depot intramuscular injections or sustained-release preparations...
Autores principales: | Omar, Anjumanara Anver, Nyaga, Godfrey, Mungai, Lucy N Wainaina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712604/ https://www.ncbi.nlm.nih.gov/pubmed/33292495 http://dx.doi.org/10.1186/s13633-020-00092-4 |
Ejemplares similares
-
Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010) -
6-Month Subcutaneous Leuprolide Acetate Effectively Suppresses Clinical Signs of Puberty in Children With Central Precocious Puberty
por: Eugster, Erica A, et al.
Publicado: (2021) -
Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study
por: Klein, Karen O, et al.
Publicado: (2023) -
Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty
por: Klein, Karen O, et al.
Publicado: (2020) -
Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study
por: Valenzise, M., et al.
Publicado: (2023)